New research led by NYU Langone Health and its Perlmutter Cancer Centre suggested that rather than analyzing the tumours themselves, genetic data from seemingly healthy tissue close to lung tumours may be a better indicator of whether cancer will recur after treatment.
According to new research headed by NYU Langone Health and its Perlmutter Cancer Centre, genetic information taken from seemingly healthy tissue near lung tumours may be a better predictor of whether cancer will return following therapy than analysis of the tumours themselves.
A recent study suggested that spinal cord stimulation (SCS) may be effective in lowering chronic pain in persons receiving active therapy with a standard anti-cancer medicine, according to researchers at Johns Hopkins University School of Medicine.
Personalization of cancer treatments has long been a goal--finding the right drugs that work for a patient's specific tumour based on specific genetic and molecular patterns. Many of these targeted therapies are highly effective, but they are not available for all cancers, including NSCLCs w
Some cancers respond well to immunotherapy, a medication therapy that prompts the immune system to target tumours, although results against lung cancer have been conflicting.